Clinical Trials · NCT02787551
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 514
- Start date
- Jul 2016
- Locations
- 124 sites, 9 countries
- Primary endpoint
- Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period